Centre for Child Health Research, Tampere University and University Hospital, Elämänaukio 2, 33520 Tampere, Finland; University of Helsinki and Helsinki University Hospital, Children's Hospital and Pediatric Research Center, Stenbäckinkatu 9, 00290 Helsinki, Finland.
MSD Finland, Keilaranta 3, 02150 Espoo, Finland,.
Vaccine. 2022 Jun 23;40(29):3942-3947. doi: 10.1016/j.vaccine.2022.04.104. Epub 2022 May 28.
Rotavirus (RV) vaccination was included in the Finnish National immunization Program (NIP) in 2009. RotaTeq (RV5) has been used exclusively with a national average vaccination coverage rate (VCR) of > 90%. While previous studies have demonstrated that inpatient rotavirus gastroenteritis (RVGE) admissions declined by as much as 96% in Finnish children ≤ 5 years old following RV vaccination introduction, no study has evaluated long-term protection after vaccination in Finland. In this study, we analyze incidence of hospital outpatient visits and inpatient admissions of gastroenteritis in children up to 7 years of age.
We first describe the incidence of RVGE, viral gastroenteritis (VGE), and acute gastroenteritis (AGE) for all Finnish children born during 2008-2011. Children were stratified by the year of birth into not-eligible, partially eligible and rotavirus vaccine-eligible (born in 2008, 2009, 2010 and 2011, respectively). Hospital inpatient and outpatient data was collected from the National Care Register for all children from birth until December 31st, 2018. We also studied RVGE incidence during 2014-2017 for children<3 years of age in municipalities with VCRs of 90% and above and municipalities with VCRs below 90%.
RVGE incidence decreased significantly soon after implementation of RV vaccination in the NIP. In vaccine-eligible cohorts, no clear peak incidence in the youngest age groups could be observed, and no RVGE cases were observed beyond 6 years after vaccination, in contrast to vaccine ineligible and partially eligible cohorts. Despite an overall high VCR in Finland, regions with high VCR had lower incidence of RVGE than regions with lower VCR.
Incidence of RVGE has remained low in all age groups during the 10 years following introduction of RV vaccine in the Finnish NIP. Differences in RVGE incidence were observed in regions with high as compared with lower VCR, highlighting the importance of maintaining high vaccination coverage.
轮状病毒 (RV) 疫苗于 2009 年纳入芬兰国家免疫计划 (NIP)。RotaTeq(RV5)一直被单独使用,全国平均疫苗接种覆盖率(VCR)>90%。虽然之前的研究表明,在 RV 疫苗接种引入后,芬兰≤5 岁儿童住院轮状病毒胃肠炎 (RVGE) 入院率下降了多达 96%,但没有研究评估芬兰接种疫苗后的长期保护作用。在这项研究中,我们分析了 0-7 岁儿童门诊和住院胃肠炎的发病率。
我们首先描述了所有 2008-2011 年出生的芬兰儿童的 RVGE、病毒性胃肠炎 (VGE) 和急性胃肠炎 (AGE) 的发病率。儿童按出生年份分为不符合条件、部分符合条件和轮状病毒疫苗符合条件(分别出生于 2008 年、2009 年、2010 年和 2011 年)。从出生到 2018 年 12 月 31 日,从国家护理登记处收集了所有儿童的住院和门诊数据。我们还研究了 2014-2017 年间在 VCR 为 90%及以上和 VCR 低于 90%的城市中,<3 岁儿童的 RVGE 发病率。
RV 疫苗纳入 NIP 后,RVGE 的发病率很快显著下降。在疫苗合格组中,在最年轻的年龄组中没有观察到明显的高峰发病率,并且在接种疫苗后 6 年以上没有观察到 RVGE 病例,而在不符合条件和部分符合条件的组中则观察到了 RVGE 病例。尽管芬兰的 VCR 总体较高,但高 VCR 地区的 RVGE 发病率低于低 VCR 地区。
在芬兰 NIP 引入 RV 疫苗后的 10 年中,所有年龄组的 RVGE 发病率均保持较低水平。在 VCR 较高的地区与较低的 VCR 地区之间观察到 RVGE 发病率的差异,突出了保持高疫苗接种覆盖率的重要性。